All In Biotech

Drug Trial Radar · NCT07861425

Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs

A Phase 1 Clinical Trial of ACE723, A Dual-Payload Antibody Drug Conjugate Targeting Glypican-3 (GPC-3), in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Who Have Failed or Progressed on Standard Immune Checkpoint Inhibitor-Containing Systemic Therapies

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

May 2030

Study completion May 2030

Sponsor

Lead sponsor
Acepodia Biotech, Inc.Industry
Sponsor type
Industry
First posted
Oct 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).

Conditions

  • Hepatocellular Carcinoma (HCC)
  • Hepatocellular Carcinoma Metastatic
  • Hepatocellular Carcinoma Non-Resectable

Interventions

  • ACE723Drug

    Intravenous Administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: To assess the safety and tolerability of ACE723 administered at multiple ascending dosesTime frame: Up to 12 months post-last dose
  2. Part 1: To determine the maximum tolerated dose (MTD) of ACE723Time frame: Up to 12 months post-last dose
  3. Part 1: To determine the recommended ACE723 doses for further evaluation in the dose expansion phaseTime frame: Up to 12 months post-last dose
  4. Part 2: To assess the safety and tolerability of ACE723 at the expansion dosesTime frame: Up to 12 months post-last dose
  5. Part 2: To determine the Recommended Phase 2 Dose (RP2D) of ACE723 for further clinical evaluationTime frame: Up to 12 months post-last dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Nanjing Tianyinshan Hospital

    Nanjing, China · Recruiting

  • Zhongshan Hospital, Fudan University

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.